KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Net Cash Flow (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Net Cash Flow data on record, last reported at $7.0 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 130.78% year-over-year to $7.0 million; the TTM value through Dec 2025 reached $7.7 million, up 106.13%, while the annual FY2025 figure was $7.7 million, 106.13% up from the prior year.
  • Net Cash Flow reached $7.0 million in Q4 2025 per PACB's latest filing, up from $1.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $850.8 million in Q1 2021 and bottomed at -$473.6 million in Q2 2021.
  • Average Net Cash Flow over 5 years is -$1.0 million, with a median of -$5.1 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: crashed 1720.29% in 2021, then skyrocketed 3033.48% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at $35.4 million in 2021, then crashed by 41.6% to $20.7 million in 2022, then crashed by 1096.02% to -$205.7 million in 2023, then surged by 89.01% to -$22.6 million in 2024, then soared by 130.78% to $7.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $7.0 million in Q4 2025, $1.7 million in Q3 2025, and -$4.1 million in Q2 2025.